Reasons for Clinical Failures by Phase
Tufts
The Tufts Center for the Study of Drug Development (Tufts CSDD) recently analyzed the reasons for clinical failures for 410 drugs that entered human testing between 2000 and 2009.
The results of this analysis show that commercial viability—as opposed to safety—is the leading cause of Phase I failures. Commercial viability played a diminishing role in the reasons for drugs failing in later clinical phases. Safety issues accounted for one-third of all drugs that failed in Phase I and Phase III studies; and for 17% of all Phase II failures.
Efficacy issues dominated both Phase II and III accounting for more than half of the total drugs that failed (54% and 52% respectively). Tufts CSDD researchers conclude that the ever-changing commercial landscape combined with insights gleaned from later-stage studies conducted among larger patient populations present ongoing drug development risk-dynamics that are difficult for sponsors to anticipate and manage.
—Tufts Center for the Study of Drug Development, https://csdd.tufts.edu/.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
